ReviewInternational journal of molecular medicine2024
Promising predictive molecular biomarkers for cervical cancer (Review).
Review in International journal of molecular medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Molecular Biomarkers of Radiosensitivity and Radioresistance in Cervical Cancer: A Systematic Review.International journal of molecular sciences · 2026Pooled it
- Identification of microRNAs as biomarkers for triage of cervical intraepithelial neoplasia in cervical scrape samples from high-risk HPV-positive women.British journal of cancer · 2026Article
- Early tumor shrinkage correlates with final EBRT response in cervical cancer patients treated with MRI-guided radiotherapy.Clinical and translational radiation oncology · 2026Article
- Article
- Co-assembled structures of FeTranslational cancer research · 2026Article
- Cervical cancer in the modern era: cutting-edge strategies for diagnosis and treatment.Japanese journal of radiology · 2026Review
- Prognostic value of glioma-associated oncogene homolog 1 and SET domain-containing protein 2 immunohistochemical scores in locally advanced cervical cancer.Oncology letters · 2026Article
- m5c-modified LINC01094 participates in epithelial-mesenchymal transition and metastasis of cervical cancer cells via the ZNF582-SIRT1/p53 axis.Mammalian genome : official journal of the International Mammalian Genome Society · 2026Article
- Identifying Key Epigenetic Modification-Related Genes for Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma and Cellular Validation.Current gene therapy · 2026Article
- Retrospective analysis of preoperative serum tumor marker levels and their correlation with pathological characteristics and prognosis in cervical cancer patients.Frontiers in genetics · 2026Article
- Exploring shared microRNA profiles in liquid-based cytology and plasma as biomarkers of high-grade intraepithelial lesions.Scientific reports · 2025Article
- A prognostic model derived from PANoptosis-associated subtypes unveils immunological features and therapeutic vulnerabilities in cervical cancer.Discover oncology · 2025Article
- MRI cytometry imaging for cervical cancer differential diagnosis: a preliminary study.BMC medical imaging · 2025Article
- miR-378, miR-20a, and miR-520a-3p can be used in a novel serum prognostic panel for cervical cancer.Scientific reports · 2025Article
- Exometabolome and Molecular Signatures Associated with HPV 16 in Cervical Cancer: Integrative Metabolomic and Transcriptomic Analysis for Biomarker Discovery.Molecules (Basel, Switzerland) · 2025Article
- Anemia and hematocrit decline in cervical cancer: unveiling clinical consequences and management strategies.Annals of medicine and surgery (2012) · 2025Review
- The Role of Ferroptosis in Women's Health and Diseases.MedComm · 2025Review
- The role of long noncoding RNA SNHG29 in malignant tumors.Discover oncology · 2025Review
- Exploring the Anticancer Activity ofLife (Basel, Switzerland) · 2025Article
- Integrating Novel and Classical Prognostic Factors in Locally Advanced Cervical Cancer: A Machine Learning-Based Predictive Model (ESTHER Study).Journal of personalized medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cervical cancer (CC) constitutes a serious public health problem. Vaccination and screening programs have notably reduced the incidence of CC worldwide by >80%; however, the mortality rate in low‑income countries remains high. The staging of CC is a determining factor in therapeutic strategies: The clinical management of early stages of CC includes surgery and/or radiotherapy, whereas radiotherapy and/or concurrent chemotherapy are the recommended therapeutic strategies for locally advanced CC. The histopathological characteristics of tumors can effectively serve as prognostic markers of radiotherapy response; however, the efficacy rate of radiotherapy may significantly differ among cancer patients. Failure of radiotherapy is commonly associated with a higher risk of recurrence, persistence and metastasis; therefore, radioresistance remains the most important and unresolved clinical problem. This condition highlights the importance of precision medicine in searching for possible predictive biomarkers to timely identify patients at risk of treatment response failure and provide tailored therapeutic strategies according to genetic and epigenetic characteristics. The present review aimed to summarize the evidence that supports the role of several proteins, methylation markers and non‑coding RNAs as potential predictive biomarkers for CC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.